Catalent (CTLT) Tops Q3 EPS by 8c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Catalent, Inc. Reports Third Quarter Fiscal 2021 Results
May 4, 2021 6:59 AM EDTQ3'21 net revenue of $1.05 billion increased 38% as reported, or 35% in constant currency, compared to Q3'20. Organic, constant-currency net revenue grew 35%, compared to Q3'20. Q3'21 net earnings of $232 million; includes a $184 million gain from the sale of the blow-fill-seal business. Q3'21 Adjusted EBITDA(1) of $274 million increased 48% as-reported, or 44% in constant currency, compared to Q3'20. Q3'21 Biologics segment net revenue of $544 million more than doubled compared to Q3'20. Increasing guidance to reflect projected net... More
